cis-1-Acetoxy-cyclohexanol-(4) | 72156-95-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cis-1-Acetoxy-cyclohexanol-(4)
• 英文别名: cis-1-Acetoxy-cyclohexanol-(4)
• CAS: 72156-95-7
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: RUYPDZUOLYBUBS-OCAPTIKFSA-N

物化性质

• 沸点：
  233.3±33.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.85
• 重原子数：
  11.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.53
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  cis-1-Acetoxy-cyclohexanol-(4) 在 ammonium hydroxide 、 水 作用下， 以 甲醇 为溶剂， 反应 15.0h， 以92.8%的产率得到cis-1,4-Cyclohexanediol
  参考文献：
  名称：

  一种顺-1,4-环己二醇的合成方法

  摘要：

  本发明公开了一种顺‑1,4‑环己二醇的合成方法，属于有机化学合成领域，该方法以4‑(烃基酰氧基)环己酮为原料，仅通过还原和水解反应就可以方便地合成出顺‑1,4‑环己二醇。该方法可以保证反应的高选择性，并且获得的产物收率高、适用于规模生产。

  公开号：

  CN107759446B
• 作为产物：
  描述：

  对苯二酚 在 吡啶 、 甲醇 、 氯仿 、 镍 作用下， 150.0 ℃ 、14.71 MPa 条件下， 生成 cis-1-Acetoxy-cyclohexanol-(4)
  参考文献：
  名称：

  76.脂环族二醇。第三部分 4-羟甲基环己醇

  摘要：

  DOI：

  10.1039/jr9490000326

文献信息

• Lanthanum(III) Isopropoxide Catalyzed Chemoselective Transesterification of Dimethyl Carbonate and Methyl Carbamates
  作者：Manabu Hatano、Sho Kamiya、Katsuhiko Moriyama、Kazuaki Ishihara

  DOI：10.1021/ol102754y

  日期：2011.2.4

  carbonate and much less reactive methyl carbamates with primary (1°), secondary (2°), and tertiary (3°) alcohols was established with the use of a lanthanum(III) complex, which was prepared in situ from lanthanum(III) isopropoxide (3 mol %) and 2-(2-methoxyethoxy)ethanol (6 mol %). In particular, corresponding carbonates and carbamates obtained were of synthetic utility from the viewpoint of the selective protection

  使用镧（III）配合物，建立了反应性较低的碳酸二甲酯和反应性较低的氨基甲酸甲酯与伯（1°），仲（2°）和叔（3°）醇的实际酯交换反应原位由异丙醇镧（III）（3摩尔％）和2-（2-甲氧基乙氧基）乙醇（6摩尔％）原位制备。特别地，从对1°-，2°-和3°-醇的选择性保护和/或脱保护的观点来看，获得的相应的碳酸盐和氨基甲酸酯具有合成用途。
• Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
  申请人：——

  公开号：US20010023250A1

  公开（公告）日：2001-09-20

  This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

  本发明涉及抑制血小板源性生长因子或p56lck酪氨酸激酶活性的喹啉/喹噁啉化合物，以及包含这些化合物的制药组合物，以及使用这些化合物治疗患有或受到涉及细胞分化，增殖，细胞外基质产生或介质释放和/或T细胞激活和增殖的疾病/病症的患者。
• Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
  申请人：Nesbit Mark

  公开号：US20070197538A1

  公开（公告）日：2007-08-23

  This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cell proliferation, and particularly treatment of brain cancer, ovarian cancer, pancreatic cancer prostate cancer, and human leukemias, such as CML, AML or ALL.

  本发明涉及针对蛋白酪氨酸激酶的强效抑制剂，单独或与抗血管生成或化疗药物协同使用，用于消除化疗难治性肿瘤内的成熟血管，以及包含这些化合物的制药组合物，并且用于治疗患有或患有涉及细胞增殖的疾病/病症的患者，特别是治疗脑癌、卵巢癌、胰腺癌、前列腺癌和人类白血病，如慢性髓细胞白血病、急性髓细胞白血病或急性淋巴细胞白血病。
• The Salinity Crisis in Western Australia: A Case of Policy Paralysis
  作者：Quentin Beresford、Harry Phillips、Hugo Bekle

  DOI：10.1111/1467-8500.00239

  日期：2001.12

  This article focuses on the Court government’s development of a State Salinity Strategy during the 1990s which took nine years from the initial announcement to the final realease. Western Australia has 70 percent of the nation’s dryland salinity, a figure widely regarded as representing a potential environmental disaster with significant flow‐on economic and social impacts. The paralysis that has surrounded decision‐making on this issue is examined as a case study in the lack of effectiveness of government policy‐making capacity on the environment. The shortcomings of the Salinity Strategy examined in the article include a lack of a leadership role for government, inadequate resourcing and weaknesses in the supporting institutional arrangements.